Back to today’s briefing

Story perspectives

Tragic Death Raises Safety Concerns for Gene Therapy

3/21/2025

39 5

Summary

Story summary

The tragic death of a 16-year-old undergoing Sarepta Therapeutics’ gene therapy, Elevidys, for Duchenne muscular dystrophy raises urgent questions about the safety of such treatments. This incident, reminiscent of Jesse Gelsinger's fatal case in 1999, reignites the debate over the delicate balance between innovation and risk in gene therapy.

1 of 1

Story summary

The tragic death of a 16-year-old undergoing Sarepta Therapeutics’ gene therapy, Elevidys, for Duchenne muscular dystrophy raises urgent questions about the safety of such treatments. This incident, reminiscent of Jesse Gelsinger's fatal case in 1999, reignites the debate over the delicate balance between innovation and risk in gene therapy.